PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06083857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06083844
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome
Phase 1
Recruiting
- Conditions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06083896
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06083883
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06066424
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT06065449
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
NeoAdjuvant Theranostic Lutetium Study: the Nautilus Trial
Phase 1
Recruiting
- Conditions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06066437
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT06065462
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06066359
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06053658
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath